Fortunately, one study suggests that CRS can be abated by using IL-1 blockade therapy such as anakinra [76]; however, the timing of therapy will have to be carefully considered to not dampen the beneficial immune activating effects of the cytokines released. This evidence concerns the gene IL1B and congenital rubella syndrome.